Is combination therapy your choice for treating BPH?
During the recent AUA annual meeting in Chicago, the association's newBPH treatment guidelines were released. Although the update contained nomajor surprises, the framework does include specific recommendations forusing combination therapy in the treatment of certain BPH sufferers.Urology Times asked urologists if they were already using combinationtherapy, consisting of an alpha-blocker and 5-alpha-reductase inhibitorand, if so, whether this regimen was showing an improvement in patient outcomes.We also asked whether they expect to perform fewer invasive procedures forBPH.All of the urologists we spoke with have used combination therapy forBPH. They all said they see benefits from its use, even if their evidenceis anecdotal.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Perioperative durvalumab (Imfinzi) plus neoadjuvant enfortumab vedotin-ejfv (Padcev) cut the risk of EFS events by 49% and death by 42% in cisplatin-ineligible MIBC.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.